Key facts
- This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 Apr 2022, 17:12.
Christopher Downs - 28 Apr 2022 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CNSP
- Reported as of
- 28 Apr 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Apr 2022, 17:12:32 UTC
- Prior SEC filing
- 14 Mar 2022
- Next SEC filing
- 10 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Downs
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 29 Apr 2022.
Change
- Previous filing in this sequence was filed on 14 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CNSP
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- Shares
- +250,000
- Change %
- +58%
- Price
- Shares after
- 681,000
- Date
- 28 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one shares of Issuer common stock.
Footnote F2
The restricted stock units set forth in this table vest as follows, subject to the grantee's continued service to the Company on each vesting date, (i) 25% of the grant will vest in four equal annual installments over 4 years; (ii) 25% of the grant will vest if within 24 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $2.00 (subject to pro rata adjustment for stock splits or similar events); (iii) 25% of the grant will vest if within 36 months from issuance the average the closing price of the Issuer common stock over a ten trading day period exceeds $4.00 (subject to pro rata adjustment for stock splits or similar events); and (iv) 25% of the grant will vest if within 24 months from issuance the Issuer achieves positive interim, clinical data as determined by its Board of Directors.
Footnote F3
Issued in connection with the reporting person's employment with the Company.